This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: Invitrogen

Earnings, analyst actions and a buyout new peppered health stock headlines on largely flat Thursday after losses earlier in the week.

Biotech company Invitrogen (IVGN) said Thursday it will buy Applera Corp.'s scientific-instrument company Applied Biosystems (ABI) in a $6.7 billion cash and stock deal. Invitrogen shares gave up 10.7% to $38.73, while Applied Biosystems climbed 5.3% to $34.16.

Invitrogen is a component of the Nasdaq biotechnology index, ended just above the flat line.

Elsewhere, China Medical (CMED) rose 17.5% to $39.28. The company said that it earned $15 million, or 53 cents per American depositary share, in the recent quarter. It recorded an adjusted profit of 66 per ADS, vs. 44 cents in the year prior. Revenue increased to $40.6 million. Analysts expected $36.8 million, on average, according to Thomson-Reuters.

Looking ahead, China Medical guided to a profit of $2.87 to $2.96 a share, on revenue in a range of $169.7 million to $175.4 million. Analysts expected $2.55 a share on $161.9 million in revenue, on average.

Meanwhile, Chindex International (CHDX), an American health-care company that provides services, equipment and products to the Chinese marketplace, sank 29.7% to $14.60. The company said revenue rose 40% to $34.6 million in the quarter ended March 31, but reported a loss of $2.7 million, or 20 cents a share, vs. a profit of $665,000, or 6 cents a share, the year prior. Chindex said the results were impacted by certain non-routine year-end adjustments as well as the interest charge related to the conversion of a JPMorgan convertible bond.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,076.45 -37.09 -0.22%
S&P 500 1,987.99 +4.46 0.22%
NASDAQ 4,475.87 +19.8540 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs